{
  "guideline_metadata": {
    "title": "Guideline on the requirements for the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials – Revision 1",
    "agency": "EMA",
    "document_id": "CHMP/QWP/185401/2004 Rev. 1",
    "version": "Revision 1",
    "publication_date": "",
    "file_checksum": "",
    "source_file_id": ""
  },
  "rules": [
    {
      "rule_id": "EMA-IMPD-S7-001",
      "applies_to": ["DS"],
      "mapped_app_sections": ["3.2.S.7", "2.2.1.S.7"],
      "requirement_level": "MUST",
      "rule_text": "Stability data on drug substance batches used in the clinical trial must be provided. A tabulated summary of stability results shall be presented.",
      "evidence_expected": ["stability table", "lot/batch identification"],
      "ui_fields_required": ["ds.stability_table", "ds.lot_information"],
      "validation": {
        "severity": "BLOCK",
        "logic": "field_present('ds.stability_table') AND field_present('ds.lot_information')"
      },
      "traceability": {
        "source_file_id": "",
        "page": 0,
        "section_heading": "3.2.S.7 Stability",
        "excerpt_snippet": "Stability data on drug substance batches used in the clinical trial must be provided..."
      }
    },
    {
      "rule_id": "EMA-IMPD-S7-002",
      "applies_to": ["DS"],
      "mapped_app_sections": ["3.2.S.7", "2.2.1.S.7"],
      "requirement_level": "MUST",
      "rule_text": "The proposed retest period (or retest date) and storage conditions for the drug substance must be stated and justified based on available stability data.",
      "evidence_expected": ["retest period statement", "storage condition specification", "justification statement"],
      "ui_fields_required": ["ds.retest_period", "ds.storage_conditions"],
      "validation": {
        "severity": "BLOCK",
        "logic": "field_present('ds.retest_period') AND field_present('ds.storage_conditions')"
      },
      "traceability": {
        "source_file_id": "",
        "page": 0,
        "section_heading": "3.2.S.7 Stability",
        "excerpt_snippet": "The proposed retest period and storage conditions for the drug substance must be stated..."
      }
    },
    {
      "rule_id": "EMA-IMPD-S7-003",
      "applies_to": ["DS"],
      "mapped_app_sections": ["3.2.S.7", "2.2.1.S.7"],
      "requirement_level": "SHOULD",
      "rule_text": "Accelerated and long-term stability studies should be initiated on at least one batch of drug substance. Results available at the time of submission should be presented.",
      "evidence_expected": ["accelerated study results", "long-term study results"],
      "ui_fields_required": ["ds.study_accelerated", "ds.study_long_term"],
      "validation": {
        "severity": "WARN",
        "logic": "field_present('ds.study_accelerated') OR field_present('ds.study_long_term')"
      },
      "traceability": {
        "source_file_id": "",
        "page": 0,
        "section_heading": "3.2.S.7 Stability",
        "excerpt_snippet": "Accelerated and long-term stability studies should be initiated on at least one batch..."
      }
    },
    {
      "rule_id": "EMA-IMPD-S7-004",
      "applies_to": ["DS"],
      "mapped_app_sections": ["3.2.S.7", "2.2.1.S.7"],
      "requirement_level": "MUST",
      "rule_text": "A commitment to conduct an ongoing stability program must be provided, particularly for Phase I applications where limited stability data are available.",
      "evidence_expected": ["stability commitment statement"],
      "ui_fields_required": ["ds.stability_commitment"],
      "validation": {
        "severity": "BLOCK",
        "logic": "field_present('ds.stability_commitment')"
      },
      "traceability": {
        "source_file_id": "",
        "page": 0,
        "section_heading": "3.2.S.7 Stability",
        "excerpt_snippet": "A commitment to conduct an ongoing stability program must be provided..."
      }
    },
    {
      "rule_id": "EMA-IMPD-S7-005",
      "applies_to": ["DS"],
      "mapped_app_sections": ["3.2.S.7", "2.2.1.S.7"],
      "requirement_level": "SHOULD",
      "rule_text": "Stress testing data (forced degradation) should be available to identify likely degradation products and validate the stability-indicating power of analytical methods.",
      "evidence_expected": ["stress study results"],
      "ui_fields_required": ["ds.study_stress"],
      "validation": {
        "severity": "WARN",
        "logic": "field_present('ds.study_stress')"
      },
      "traceability": {
        "source_file_id": "",
        "page": 0,
        "section_heading": "3.2.S.7 Stability",
        "excerpt_snippet": "Stress testing should be available to identify likely degradation products..."
      }
    },
    {
      "rule_id": "EMA-IMPD-P8-001",
      "applies_to": ["DP"],
      "mapped_app_sections": ["3.2.P.8", "2.2.1.P.8"],
      "requirement_level": "MUST",
      "rule_text": "Stability data on drug product batches (or representative formulations) used in the clinical trial must be provided in tabulated form.",
      "evidence_expected": ["stability table", "lot/batch identification"],
      "ui_fields_required": ["dp.stability_table", "dp.lot_information"],
      "validation": {
        "severity": "BLOCK",
        "logic": "field_present('dp.stability_table') AND field_present('dp.lot_information')"
      },
      "traceability": {
        "source_file_id": "",
        "page": 0,
        "section_heading": "3.2.P.8 Stability",
        "excerpt_snippet": "Stability data on drug product batches used in the clinical trial must be provided..."
      }
    },
    {
      "rule_id": "EMA-IMPD-P8-002",
      "applies_to": ["DP"],
      "mapped_app_sections": ["3.2.P.8", "2.2.1.P.8"],
      "requirement_level": "MUST",
      "rule_text": "The proposed shelf-life and storage conditions for the drug product must be stated and justified based on available stability data.",
      "evidence_expected": ["shelf-life statement", "storage condition specification", "justification statement"],
      "ui_fields_required": ["dp.shelf_life", "dp.storage_conditions"],
      "validation": {
        "severity": "BLOCK",
        "logic": "field_present('dp.shelf_life') AND field_present('dp.storage_conditions')"
      },
      "traceability": {
        "source_file_id": "",
        "page": 0,
        "section_heading": "3.2.P.8 Stability",
        "excerpt_snippet": "The proposed shelf-life and storage conditions must be stated and justified..."
      }
    },
    {
      "rule_id": "EMA-IMPD-P8-003",
      "applies_to": ["DP"],
      "mapped_app_sections": ["3.2.P.8", "2.2.1.P.8"],
      "requirement_level": "SHOULD",
      "rule_text": "Accelerated and long-term stability studies should be initiated in accordance with ICH guidelines. For Phase II/III, comprehensive stability data including both accelerated and long-term results should be presented.",
      "evidence_expected": ["accelerated study results", "long-term study results"],
      "ui_fields_required": ["dp.study_accelerated", "dp.study_long_term"],
      "validation": {
        "severity": "WARN",
        "logic": "field_present('dp.study_accelerated') AND field_present('dp.study_long_term')"
      },
      "traceability": {
        "source_file_id": "",
        "page": 0,
        "section_heading": "3.2.P.8 Stability",
        "excerpt_snippet": "Accelerated and long-term stability studies should be initiated in accordance with ICH..."
      }
    },
    {
      "rule_id": "EMA-IMPD-P8-004",
      "applies_to": ["DP"],
      "mapped_app_sections": ["3.2.P.8", "2.2.1.P.8"],
      "requirement_level": "MUST",
      "rule_text": "In-use stability data must be provided for drug products that require reconstitution, dilution, or mixing prior to administration, or for multi-dose products, unless immediate use after preparation is justified.",
      "evidence_expected": ["in-use stability data", "justification statement"],
      "ui_fields_required": ["dp.in_use_stability"],
      "validation": {
        "severity": "BLOCK",
        "logic": "IF product.requires_reconstitution OR product.is_multi_dose THEN field_present('dp.in_use_stability') OR field_present('dp.in_use_justification')"
      },
      "traceability": {
        "source_file_id": "",
        "page": 0,
        "section_heading": "3.2.P.8 Stability",
        "excerpt_snippet": "In-use stability data must be provided for products requiring reconstitution, dilution..."
      }
    },
    {
      "rule_id": "EMA-IMPD-P8-005",
      "applies_to": ["DP"],
      "mapped_app_sections": ["3.2.P.8", "2.2.1.P.8"],
      "requirement_level": "SHOULD",
      "rule_text": "Photostability testing should be conducted on at least one batch in accordance with ICH Q1B.",
      "evidence_expected": ["photostability study"],
      "ui_fields_required": ["dp.study_photostability"],
      "validation": {
        "severity": "WARN",
        "logic": "field_present('dp.study_photostability')"
      },
      "traceability": {
        "source_file_id": "",
        "page": 0,
        "section_heading": "3.2.P.8 Stability",
        "excerpt_snippet": "Photostability testing should be conducted on at least one batch..."
      }
    },
    {
      "rule_id": "EMA-IMPD-P8-006",
      "applies_to": ["DP"],
      "mapped_app_sections": ["3.2.P.8", "2.2.1.P.8"],
      "requirement_level": "MUST",
      "rule_text": "A commitment to conduct an ongoing stability program for the drug product must be provided.",
      "evidence_expected": ["stability commitment statement"],
      "ui_fields_required": ["dp.stability_commitment"],
      "validation": {
        "severity": "BLOCK",
        "logic": "field_present('dp.stability_commitment')"
      },
      "traceability": {
        "source_file_id": "",
        "page": 0,
        "section_heading": "3.2.P.8 Stability",
        "excerpt_snippet": "A commitment to conduct an ongoing stability program must be provided..."
      }
    },
    {
      "rule_id": "EMA-IMPD-GEN-001",
      "applies_to": ["DS", "DP"],
      "mapped_app_sections": ["3.2.S.7", "3.2.P.8", "2.2.1.S.7", "2.2.1.P.8"],
      "requirement_level": "MUST",
      "rule_text": "Storage conditions used in stability studies must be described, including temperature and, where applicable, humidity conditions in accordance with ICH Q1A(R2).",
      "evidence_expected": ["storage condition specification"],
      "ui_fields_required": ["ds.storage_conditions", "dp.storage_conditions"],
      "validation": {
        "severity": "BLOCK",
        "logic": "field_present('ds.storage_conditions') OR field_present('dp.storage_conditions')"
      },
      "traceability": {
        "source_file_id": "",
        "page": 0,
        "section_heading": "Stability",
        "excerpt_snippet": "Storage conditions used in stability studies must be described..."
      }
    },
    {
      "rule_id": "EMA-IMPD-GEN-002",
      "applies_to": ["DS", "DP"],
      "mapped_app_sections": ["3.2.S.7", "3.2.P.8", "2.2.1.S.7", "2.2.1.P.8"],
      "requirement_level": "SHOULD",
      "rule_text": "The stability specification should be consistent with the release specification, and stability-indicating methods should be used. Any differences between stability and release specifications should be justified.",
      "evidence_expected": ["specification reference"],
      "ui_fields_required": ["ds.specification_reference", "dp.specification_reference"],
      "validation": {
        "severity": "WARN",
        "logic": "manual_review_required"
      },
      "traceability": {
        "source_file_id": "",
        "page": 0,
        "section_heading": "Stability",
        "excerpt_snippet": "The stability specification should be consistent with the release specification..."
      }
    },
    {
      "rule_id": "EMA-IMPD-GEN-003",
      "applies_to": ["DS", "DP"],
      "mapped_app_sections": ["3.2.S.7", "3.2.P.8", "2.2.1.S.7", "2.2.1.P.8"],
      "requirement_level": "MUST",
      "rule_text": "Batch information for stability studies must include batch number, batch size, manufacturing site, and date of manufacture (or date placed on stability).",
      "evidence_expected": ["lot/batch identification"],
      "ui_fields_required": ["ds.lot_information", "dp.lot_information"],
      "validation": {
        "severity": "BLOCK",
        "logic": "field_present('ds.lot_information') OR field_present('dp.lot_information')"
      },
      "traceability": {
        "source_file_id": "",
        "page": 0,
        "section_heading": "Stability",
        "excerpt_snippet": "Batch information must include batch number, batch size, manufacturing site..."
      }
    }
  ],
  "glossary": [
    {
      "term": "retest period",
      "definition": "The period of time during which the drug substance is expected to remain within its specification, provided that it has been stored under the defined conditions. After the retest period, a batch may be retested and used immediately.",
      "source_page": 0
    },
    {
      "term": "shelf life",
      "definition": "The time period during which a drug product is expected to remain within the approved shelf-life specification, provided that it is stored under the conditions defined on the container label.",
      "source_page": 0
    },
    {
      "term": "accelerated testing",
      "definition": "Studies designed to increase the rate of chemical degradation or physical change of a drug substance or drug product by using exaggerated storage conditions as part of the formal stability studies.",
      "source_page": 0
    },
    {
      "term": "long-term testing",
      "definition": "Stability studies under the recommended storage condition for the retest period or shelf life proposed (or approved) for labeling.",
      "source_page": 0
    },
    {
      "term": "in-use stability",
      "definition": "Stability of a drug product after opening of the container, reconstitution or dilution according to the labeling instructions, simulating use of the product in practice.",
      "source_page": 0
    },
    {
      "term": "stress testing",
      "definition": "Studies undertaken to elucidate the intrinsic stability of the drug substance or drug product. These are a component of the development strategy and are normally carried out under more severe conditions than those used for accelerated testing.",
      "source_page": 0
    },
    {
      "term": "IMPD",
      "definition": "Investigational Medicinal Product Dossier — the quality, non-clinical, and clinical documentation submitted to support a clinical trial application in the EU.",
      "source_page": 0
    },
    {
      "term": "stability commitment",
      "definition": "A formal assurance by the applicant that ongoing or additional stability studies will be performed post-submission and that any changes in storage conditions or retest period/shelf life will be reported.",
      "source_page": 0
    }
  ]
}
